川寧生物(301301.SZ):目前的儲備產品中有泛酸鈣項目,也就是維生素B5,正在建設中
格隆匯8月23日丨有投資者向川寧生物(301301.SZ)提問,“請問公司是否能為維生素產業提供產品或技術服務?目前,公司是否有開發新的產業技術?公司核心業務分為哪幾塊?”
川寧生物回覆稱,公司目前的儲備產品中有泛酸鈣項目,也就是維生素B5,目前該項目正在建設中。公司核心業務分為“生物發酵”和“合成生物”2個業務板塊,兩個業務板塊之間密不可分,相互協同。在合成生物學領域,公司聚焦保健品原料、生物農藥、高附加值天然產物、高端化粧品原料等板塊,目前已有紅沒藥醇、五羥色氨酸、麥角硫因等幾個產品,明年將在鞏留合成生物學基地進行生產。在生物發酵領域,目前公司主要產品包括硫氰酸紅黴素、頭孢類中間體(7-ACA、7-ADCA、D-7ACA)、青黴素中間體(6-APA、青黴素G鉀鹽)、熊去氧膽酸粗品、輔酶Q10菌絲體等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.